Umbelliferone

Umbelliferone

SCHEMBL542514

COP(=O)(O)O.O=c1ccc2ccc(O)cc2o1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 11/20 0.72
CA12 O43570 10/20 0.72
MCL1 Q07820 6/20 0.72
CA1 P00915 6/20 0.72
AKR1B1 P15121 5/20 0.72
KDM4E B2RXH2 5/20 0.72
ALDH1A1 P00352 4/20 0.72
HPGD P15428 4/20 0.72
HSD17B10 Q99714 4/20 0.72
GLA P06280 4/20 0.72
GAA P10253 4/20 0.72
ERAP1 Q9NZ08 4/20 0.72
CASP1 P29466 3/20 0.72
CASP7 P55210 3/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
TDP1 Q9NUW8 2/20 0.72
POLB P06746 3/20 0.53
CA7 P43166 4/20 0.53
CA4 P22748 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Umbelliferone SCHEMBL2246676 0.89 CA9 (0.85) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL11137587 0.85 CA9 (1.00) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL29396070 0.85 CA9 (1.00) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL29624448 0.85 CA9 (1.00) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL22018 0.85 CA9 (1.00) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL307982 0.83 CA9 (0.96) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL27427599 0.83 CA9 (0.96) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL27700116 0.83 CA9 (0.96) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL2767044 0.83 CA9 (0.96) CA9CA12MCL1CA1AKR1B1
Umbelliferone SCHEMBL27915972 0.83 CA9 (0.96) CA9CA12MCL1CA1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0452330-A4 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM 1992-10-14 EP claimed
EP-0452330-A1 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM TOTEM HEALTH SCIENCES, INC. (CA) 1991-10-23 EP claimed
WO-1990004644-A1 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM TOTEM HEALTH SCIENCES, INC. (CA) 1990-05-03 WO claimed
CN-113631572-A GRP78 and/or HSP70 inhibitors for therapeutic use GHP科学有限公司 2021-11-09 CN disclosed
US-8481678-B2 Peptide-based tooth whitening reagents E I DU PONT DE NEMOURS AND COMPANY (US) 2013-07-09 US disclosed
US-8354381-B2 Peptide compositions for oral care systems E I DU PONT DE NEMOURS AND COMPANY (US) 2013-01-15 US disclosed
CN-102770208-A Living organism load detection using microparticles 3M INNOVATIVE PROPERTIES CO 2012-11-07 CN disclosed
EP-2413948-A2 PEPTIDE COMPOSITIONS FOR ORAL CARE SYSTEMS E. I. du Pont de Nemours and Company (US) 2012-02-08 EP disclosed
CN-102325596-A Living organism load detection using microparticles 3M INNOVATIVE PROPERTIES CO 2012-01-18 CN disclosed
US-20100311641-A1 PEPTIDE-BASED BODY SURFACE COLORING REAGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-12-09 US disclosed
WO-2010117753-A2 PEPTIDE COMPOSITIONS FOR ORAL CARE SYSTEMS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-10-14 WO disclosed
US-6232095-B1 KIT FOR DETECTING MISMATCHES AND MUTANTS; CANCER DIAGNOSIS THOMAS JEFFERSON UNIVERSITY 2001-05-15 US disclosed
US-5736334-A AMPLIFICATION BY DNA HYDRIDIZATION ABBOTT LABORATORIES (US) 1998-04-07 US disclosed
EP-0785996-A1 NUCLEOTIDE SEQUENCES AND PROCESS FOR AMPLIFYING AND DETECTION OF HEPATITIS B VIRUS ABBOTT LABORATORIES (US) 1997-07-30 EP disclosed
EP-0785996-A4 1997-07-30 EP disclosed
WO-1995002690-A1 NUCLEOTIDE SEQUENCES AND PROCESS FOR AMPLIFYING AND DETECTION OF HEPATITIS B VIRUS ABBOTT LABORATORIES (US) 1995-01-26 WO disclosed
US-5250412-A Swab device and method for collecting and analyzing a sample DIAMEDIX CORPORATION (US) 1993-10-05 US disclosed
EP-0452330-A4 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM 1992-10-14 EP disclosed
EP-0452330-A1 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM TOTEM HEALTH SCIENCES, INC. (CA) 1991-10-23 EP disclosed
WO-1990004644-A1 METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM TOTEM HEALTH SCIENCES, INC. (CA) 1990-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311641-A1 PEPTIDE-BASED BODY SURFACE COLORING REAGENTS CUTA, PRAP1, RBP1 CA9 3812/4885CA12 1520/4885MCL1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.